On the eve of a deadline for the U.K. Department of Health to release a detailed framework on the country's proposed value-based pricing system, patient groups are demanding a seat at the negotiating table with the agency and the Association of the British Pharmaceutical Industry.

Meanwhile, a consortium of biostatisticians and health economists has released a report challenging QALYs, the primary metric for determining the value of drugs in the U.K.